Synergistic antitumour effect of recombinant human tumour necrosis factor α with melphalan in isolated limb perfusion in the rat

British Journal of Surgery

Volumn 83, Issue 4, 1996, Pages 551-555

  Manusama, E R ^a   Nooijen, P T G A ^b   Stavast, J ^a   Durante, N M C ^a   Marquet, R L ^a   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; LIMB PERFUSION; MALE; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOMA;

ANIMALS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HINDLIMB; HUMANS; MALE; MELPHALAN; RATS; SARCOMA, EXPERIMENTAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029985727     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800830438     Document Type: Article

References (34)

1. Liénard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52-60.
2. Liénard D, Eggermont AM, Schraffordt Koops H et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 1994; 4(Suppl 1): 21-6.
3. Eggermont AMM, Liénard D, Schrafford Koops H, Rosenkaimer F, Lejeune FJ. Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNFα in combination with interferon-gamma and melphalan. In: Fiers W, Buurman WA, eds. Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Basel: Karger, 1993: 239-43.
4. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-32.
5. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977; 185: 555-64.
6. Klaase JM, Kroon BBR, Benckhuysen C, van Geel AN, Albus-Lutter ChE, Wieberlink J. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989; 64: 616-21.
7. Spriggs DR, Sherman ML, Michie H et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80: 1039-44.
8. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant human tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 2986-9.
9. Chapman PB, Lester TJ, Casper ES et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987; 5: 1942-51.
10. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6: 1328-34.
11. Spriggs DR, Yates SW. Cancer chemotherapy. Experiences with TNF administration in humans. In: Beutler B, ed. Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. New York: Raven Press, 1992: 383-406.
12. Asher A, Mulé JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987; 138: 963-74.
13. Benckhuijsen C, Kroon BBR, van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988; 14: 157-63.
14. Marquet RL, Schellekens H, Westbroek DL, Jeekel J. Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats. Int J Cancer 1983; 31: 223-6.
15. Kort WJ, Zondervan PE, Hulsman LO, Weijma IM, Westbroek DL. Incidence of spontaneous tumors in a group of retired breeder female brown Norway rats. J Natl Cancer Inst 1984; 72: 709-13.
16. Prehn RT, Main JW. Immunity to methylcholantrene-induced sarcomas. J Natl Cancer Inst 1957; 18: 769-78.
17. Kramer SM, Carver ME. Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods 1986; 93: 201-6.
18. Benckhuijsen C, Van Dijk WJ, Van't Hoff SC. High-flow isolation perfusion of the rat hind limb in vivo. J Surg Oncol 1982; 21: 249-57.
19. Manusama ER, Durante NMC, Marquet RL, Eggermont AMM. Ischemia promotes the antitumor effect of tumor necrosis factor alpha (TNFα) in isolated limb perfusion in the rat. Reg Cancer Treat 1994; 7: 155-9.
20. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
21. Watanabe N, Niitsu Y, Umeno H et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48: 2179-83.
22. Bloksma N, van de Wiel PA, Kuper CF, Hofhuis FMA. Multiple facets of induction of tumour necrosis. Annales de L'institut Pasteur-Immunologie 1988; 139: 294-9.
23. Nawroth P, Handley D, Matsueda G et al. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 1988; 168: 637-47.
24. Renard N, Nooijen P, Schalkwijk L et al. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol 1995; 176: 279-87.
25. Eggermont AMM, Schraffordt Koops H, Lienard D, Lejeune FJ, Oudkerk M. Destruction of tumor associated vessels by isolated limb perfusion with tumor necrosis factor-α: angiographic observations in sarcoma patients. Eur J Surg Oncol 1994; 20: 403 (Abstract).
26. Kachel DL, Martin WJ II. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther 1994; 268: 42-6.
27. Key ME, Brandhorst JS, Hanna MG Jr. Synergistic effects of active therapy and specific immunotherapy and chemotherapy in guinea pigs with disseminated cancer. J Immunol 1983; 130: 2987-92.
28. Folli S, Pelegrin A, Chalandon Y et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993; 53: 829-36.
29. Renard N, Liénard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer 1994; 57: 656-63.
30. al Attiyah RA, Rosen H, Rook GAW. A model for the investigation of factors influencing haemorrhagic necrosis mediated by tumour necrosis factor in tissue sites primed with mycobacterial antigen preparations. Clin Exp Immunol 1992; 88: 537-42.
31. Yi ES, Ulich TR. Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am J Pathol 1992; 140: 659-63.
32. + cells. Cancer Immunol Immunother 1989; 28: 153-6.
33. Weksler B, Blumberg D, Lenert JT, Ng B, Fong Y, Burt ME. Isolated single-lung perfusion with TNF-α in a rat sarcoma lung metastases model. Ann Thorac Surg 1994; 58: 328-32.
34. Progrebniak HW, Witt CJ, Terrill R et al. Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg 1994; 57: 1477-83.